AbbVie, Janssen Win IP Fight Over Cancer Drug Imbruvica
A Delaware federal judge on Thursday ruled in favor of AbbVie and Janssen Biotech Inc. in their 2019 suit against Alvogen over its planned generic version of the blockbuster cancer drug...To view the full article, register now.
Already a subscriber? Click here to view full article